CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH In 2023, patents for the two blockbusters Humira and Stelara will expire. The patents for Aranesp, Rituxan, Simponi, and others will expire in 2024, and in 2025, six more blockbuster drugs will experience patent expiration, opening the field to a rush of biosimilars. That could create an environment of significantly reduced drug prices.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
